

Medicines Patent Pool Governance Board Meeting #41

12-13 May 2026
In-person meeting

Attendees

Governance Board Members:

Marie-Paule Kieny (Chair), Grégory Bonnaud (Vice-Chair and Treasurer), Mojisola Christianah Adeyeye, Maureen Luba, Peter Maybarduk, Christian Miculka, Govindarajan Narayanan, Ntobeko Ntusi, Mathieu Saint-Arnaud, Maximiliano Diego Santa Cruz Scantlebury, Pushpagiri Vijayaraghavan.

Excused Board Members:

N/A

Non-voting Members:

Jackson Hungu – Unitaid Representative¹, Marion (Amy) Dietterich – World Intellectual Property Organization Representative; Deusdedit Mubangizi – World Health Organization Representative²; Peter Beyer – Expert Advisory Group Chair.

Excused Non-voting Members:

Tanuja Garde – World Trade Organization Representative

Medicines Patent Pool Foundation Management Team:

Charles Gore – Executive Director

Esteban Burrone – Policy, Strategy and Market Access Director, Jane Caldwell – Chief Operating Officer, Ike James – Technology Transfer Director, Gelise McCullough – Communications Director, Chan Park – General Counsel, Natacha Debbané³ – Business Development, Partnerships and in-licensing Senior Manager, Aditi Das³ – Head of Alliance and India Office, Meghmala Das³ - Business Development Senior Alliance Manager, Ruth Foley³ – Monitoring and Evaluation Senior Manager, Cheleka Mpande³ - Partnerships Specialist, Gosha Stehle³ – Senior HR Manager, Deborah Woodford³ – Head of Finance, Agnese Tonnina – Secretary of the Board.

¹ Attended remotely on 12 May. Left the meeting at 12:35

² Replacing Dr Yukiko Nakatani

³ Attended specific sessions only

Summary of Decisions

The Governance Board of the Medicines Patent Pool:

1. Approved the agenda of the Governance Board Meeting #41.
2. On period of exclusivity, agreed to keep article 4 of the Statutes without amendment. It was further agreed that, in exceptional cases, MPP may consider issuing licences to a single manufacturer for a limited period of time, in cases in which further development of a licensed product is necessary. Any such proposed exceptional arrangement shall be submitted to the Board for review and approval prior to being reflected in the relevant sublicense agreement.
3. Agreed to replace paragraph 3.2.1. of the Transparency Policy: “MPP will annually publish a prioritization report on the MPP website, detailing the products that it targets for in-licensing” with the following text: "MPP will regularly publish on its website strategic priorities for in-licensing in relation to the disease areas it operates in".
4. Approved the continuation of RegPaL Lite for a further six months, while requesting that additional information on development and maintenance costs and the overall sustainability of the platform be presented at the next Board meeting to support a more informed decision.
5. On quality assurance requirements for regional manufacturing:
 - Agreed that the current MPP Statutes and quality assurance framework already provide some flexibility for the Board to approve alternative mechanisms in exceptional circumstances, provided that appropriate product quality can still be ensured. As such, agreed that the Statutes shall not be amended.
 - Agreed that until more national regulatory authorities (NRAs) are recognised as WLAs, case by case approvals by the Board will consider risk mitigation measures such as approvals by an NRA that has reached Maturity levels 3 or 4 (ML3/ML4), as per the WHO Global Benchmarking Tool. This is consistent with WHO’s guidance to MPP in January 2023 for C-TAP licences.
 - Authorised the Management to continue progressing the licensing and technology transfer opportunities presented, subject to licensees obtaining approval from an NRA recognised as WHO ML3/ML4 for the relevant product. In cases where manufacturers are located in countries whose NRAs have not yet achieved WHO ML3/ML4 status, governments should commit to supporting their NRAs in reaching the required maturity level before product launch.
6. Approved the 2025 financial statements, auditors’ report, and the 2025 annual report.
7. Approved the list of 2025 single sourcing presented by the Management.
8. Approved the 2026 budget reforecast totalling CHF 12.8 million.

9. Requested the Management to continue closely monitoring organisational growth and staffing levels and to present to the Board future scenario-planning exercises and staffing projections under different funding environments in order to support more forward-looking Board discussions on sustainability, organisational structure and resource allocation.
10. Approved the proposed changes to the Financial Management Policy (V7) including the addition of Continia and the Internal Control Matrix (ICM).
11. Approved the 2025 Key Organisational Indicators (KOIs) Results Report.
12. Approved the proposed KOI framework for the 2026–2030 strategy period, stressing that no additional KOIs shall be introduced in the future.
13. Invited Board Member Maximiliano Santa Cruz to serve a third term from 15 October 2026 to 14 October 2029, and Board Member Govindarajan Narayanan to serve a second term from 1 November 2026 to 31 October 2029.